Literature DB >> 27848011

Clinical value of antistreptolysin O levels in adult patients with tonsillitis: report I.

Vladimir Trushin1, Moshe Englender2.   

Abstract

To assess the clinical value of antistreptolysin O (ASO) level in adult patients with acute tonsillitis of group A beta-hemolytic streptococcus (GABHS) etiology and its interaction with the Centor score and throat cultures data. ASO antibody titers and throat cultures were obtained from 260 adult patients with acute tonsillitis of GABHS etiology initially proven by the Centor score. The results were compared with the group of 100 adult patients with recurrent tonsillitis who underwent tonsillectomy and with the group of 100 healthy adults. Throat cultures revealed GABHS-positive results in 69 acute cases (26.5%) and in 24 recurrent cases (24%), i.e., with no significant differences between the groups (p = 0.845). There was no significant difference between cases with GABHS-positive and with GABHS-negative throat culture in ASO titers results (mean 250 and 280, respectively, p = 0.44) but these titers were significantly higher than established normative data (p < 0.01). For the group of recurrent tonsillitis cases, the mean ASO titer was 363 being significantly higher in comparison with acute cases (p = 0.015). The ASO antibody titers are significantly higher than normative ranges in cases of acute tonsillitis in adults. The detection of the elevated titers may lead to early antibiotherapy to tonsillitis. The Centor score is supported by the ASO data and less supported by throat cultures data. Further research should reveal if these titers might have predictive value for possible further recurrence or serve as an indicator for tonsillectomy in cases of recurrent tonsillitis.

Entities:  

Keywords:  Acute tonsillitis; Antistreptolysin O; Centor score; Group A beta-hemolytic streptococcus

Mesh:

Substances:

Year:  2016        PMID: 27848011     DOI: 10.1007/s00405-016-4393-7

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  25 in total

1.  Evidence based case report. Sore throat: diagnostic and therapeutic dilemmas.

Authors:  A Graham; T Fahey
Journal:  BMJ       Date:  1999-07-17

2.  Immune response to group A streptococcal infections.

Authors:  E M Ayoub
Journal:  Pediatr Infect Dis J       Date:  1991-10       Impact factor: 2.129

3.  Studies on the pathogenesis of rheumatic fever; the antistreptolysin titre in acute tonsillitis, in patients admitted for tonsillectomy, in rheumatic fever and in control groups.

Authors:  L KIRSCHNER; D J A GALLAGHER
Journal:  N Z Med J       Date:  1950-04

4.  Streptococcal tonsillitis as a cause of urticaria: tonsillitis and urticaria.

Authors:  G Calado; G Loureiro; D Machado; B Tavares; C Ribeiro; C Pereira; A S Luís
Journal:  Allergol Immunopathol (Madr)       Date:  2011-10-05       Impact factor: 1.667

5.  The rational clinical examination. Does this patient have strep throat?

Authors:  M H Ebell; M A Smith; H C Barry; K Ives; M Carey
Journal:  JAMA       Date:  2000-12-13       Impact factor: 56.272

6.  The significance of stress hormones (glucocorticoids, catecholamines) for eruptions and spontaneous remission phases in psoriasis.

Authors:  B A Weigl
Journal:  Int J Dermatol       Date:  2000-09       Impact factor: 2.736

7.  Refining clinical diagnosis with likelihood ratios.

Authors:  David A Grimes; Kenneth F Schulz
Journal:  Lancet       Date:  2005 Apr 23-29       Impact factor: 79.321

8.  Detection of antibody isotypes to streptolysin O by dot ELISA.

Authors:  S F Barbosa; P M Nakamura; S Hoshino-Shimizu
Journal:  Braz J Med Biol Res       Date:  1996-06       Impact factor: 2.590

9.  Predicting streptococcal pharyngitis in adults in primary care: a systematic review of the diagnostic accuracy of symptoms and signs and validation of the Centor score.

Authors:  Jolien Aalbers; Kirsty K O'Brien; Wai-Sun Chan; Gavin A Falk; Conor Teljeur; Borislav D Dimitrov; Tom Fahey
Journal:  BMC Med       Date:  2011-06-01       Impact factor: 8.775

10.  ANTIGENIC STREPTOCOCCAL HEMOLYSIN.

Authors:  E W Todd
Journal:  J Exp Med       Date:  1932-01-31       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.